Phenotypes Associated with This Genotype

Genotype
MGI:6116291

• Allelic Composition: Gas2l3^{tm1c(EUCOMM)Hmgu}/Gas2l3^{tm1c(EUCOMM)Hmgu}; Gt(ROSA)26Sor^{tm2(cre/ERT2)Brn}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cardiovascular system

cardiovascular system phenotype ( J:244087 )

N • no increase in heart weight, no dilation, and no fibrosis when tamoxifen is used to induce loss of expression in neonatal mice unlike when expression is absent in embryonic stages

abnormal fetal cardiomyocyte morphology ( J:244087 )

• in cultured cardiomyocytes after tamoxifen induction 22% become binucleated while very few cells were binucleate before tamoxifen exposure

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

cellular

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

abnormal mitotic cytokinesis ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission

muscle

abnormal fetal cardiomyocyte proliferation ( J:244087 )

• increase in the proportion of cardiomyocytes with unresolved cytokinetic midbody structures indicating failed abscission